Epcoritamab 治疗复发/难治性大 B 细胞淋巴瘤：关键性 EPCORE NHL-1 试验的 2 年随访

Primary results (median follow-up, 10. 7 months) from the pivotal EPCORE NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy.

We report long-term efficacy and safety results in patients with LBCL (N = 157; 25. 1-month median follow-up). As of April 21, 2023, overall response rate was 63. 1% and complete response (CR) rate was 40. 1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27. 8% and 44. 6%, respectively. An estimated 64. 2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65. 1% and 78. 2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45. 4% had MRD negativity, which correlated with longer PFS and OS.

CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index 3. The most common treatment-emergent adverse events were cytokine release syndrome (51. 0%), pyrexia (24.

8%), fatigue (24. 2%), and neutropenia (23. 6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials. gov Registration: NCT03625037).